Myeloperoxidase deficiency, parodontits, chronic inflammation Endothelial Dysfunction
Conditions
Interventions
Group 1: Myeloperoxidase deficient will be screened and pre as well as 1 day, 8 weeks and 6 months after parodontitis treatment surveyed. Therefore laboratory parameters will be evaluated. The endothe
Sponsors
Medizinische Klinik III, Herzzentrum der Universität zu Köln
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: MPXI deficient: = 18; MPXI controls: = 10
Exclusion criteria
Exclusion criteria: minority (< 18 years), reduced ability to reason and capacity to contract, pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in endothelial function after parodontitis treatment evaluated bei FMD/NMD-measurement pre-treatment as well as day 1, week 8 and 6 months post treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood levels of inflammatory parameters: CRP, IL-6, BSR, MPO-levelsl, MPO-activity pre treatment as well as day 1, week 8 and month 6 post treatment. Evaluation of cardiovascular disease two years after study inclusion (anamnestically) | — |
Countries
Germany
Contacts
Public ContactHenning Guthoff
Medizinische Klinik III, Herzzentrum der Universität zu Köln
Outcome results
None listed